跳至主要内容
临床试验/NCT00141375
NCT00141375已完成3 期

An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.

Pfizer7 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2002年8月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
132
试验地点
7
主要终点
Safety and Efficacy

研究概览

简要总结

To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.
  • Must have received study medication under double-blind conditions.

排除标准

  • Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.

结局指标

主要结局

Safety and Efficacy

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (7)

Loading locations...

相似试验